Literature DB >> 14684237

Relapsing-remitting, corticosteroid-sensitive, varicella zoster virus optic neuritis.

Misha L Pless1, Saleem I Malik.   

Abstract

We report a 13-year-old male who presented with bilateral disc edema after a febrile illness. Rapid loss of vision prompted corticosteroids treatment, which reversed the visual loss and optic disc findings. Both his visual function and disc edema proved exceedingly sensitive to steroids, and he required increasingly slow and prolonged corticosteroids taper to avoid relapse over a period of 1 year. Ultimately, profound visual loss was reversed three times and only after exceptionally slow steroid weaning. Comprehensive systemic investigations and neuroimaging were initially unrevealing. Late in the course of disease, evidence of seroconversion was identified in his serum and cerebrospinal fluid with positive varicella zoster virus antibodies titers. Varicella zoster virus-related optic nerve pathology may present clinically with profound visual loss and disc edema and may reverse only with high-dose corticosteroids treatment. Physicians should carefully consider retesting with late varicella zoster virus titer in patients with relapsing-remitting, steroid-sensitive optic neuritides.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14684237     DOI: 10.1016/s0887-8994(03)00306-0

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  2 in total

1.  Optic neuritis in an adult patient with chickenpox.

Authors:  Ana Rita Azevedo; Rita Simões; Filipe Silva; Susana Pina; Cristina Santos; Peter Pêgo; Filomena Silva; Susana Teixeira
Journal:  Case Rep Ophthalmol Med       Date:  2012-12-19

2.  Isolated optic neuritis with a concurrent abnormal trigeminal nucleus on imaging: case report of a rare complication of herpes zoster ophthalmicus.

Authors:  Kavin Vanikieti; Anuchit Poonyathalang; Panitha Jindahra; Piyaphon Cheecharoen; Patchalin Patputtipong; Tanyatuth Padungkiatsagul
Journal:  BMC Neurol       Date:  2018-10-04       Impact factor: 2.474

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.